AbbVie signs agreement to acquire Aliada for $1.4bn
AbbVie has entered a definitive agreement to acquire all outstanding equity of Aliada Therapeutics in a $1.4bn cash deal. The…
Central Nervous System
-
-
AbbVie and Richter partner for neuropsychiatric treatments
AbbVie has entered a collaboration with Hungary-based pharmaceutical company Gedeon Richter to develop new treatments for neuropsychiatric conditions. The agreement…
-
Lilly’s Kisunla does not demonstrate “good value” for UK’s NHS
Eli Lilly’s Kisunla (donanemab) will not yet be made available to Alzheimer’s patients in the UK after the National Institute…
-
EU CHMP recommends AstraZeneca and Ionis’ Wainzua for ATTRv-PN
The European Union's Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of AstraZeneca and Ionis Pharmaceuticals’…
-
Avadel wins FDA approval for narcolepsy drug Lumryz in children
Paediatric patients with narcolepsy will now have access to Avadel’s Lumryz (sodium oxybate) after the US Food and Drug Administration…
-
FDA approves AbbVie’s VYALEV for advanced Parkinson’s treatment
The US Food and Drug Administration (FDA) has approved AbbVie's VYALEV (foscarbidopa and foslevodopa) to treat motor fluctuations in adults…
-
Health Canada approves Acadia’s DAYBUE for Rett syndrome
Acadia Pharmaceuticals has received marketing authorisation from Health Canada for DAYBUE (trofinetide) to treat Rett syndrome in adult and paediatric…
-
J&J trims neuroscience pipeline – seltorexant in Alzheimer’s disease dropped
Johnson and Johnson (J&J) has cleaved several clinical programmes, including a Phase II study evaluating seltorexant in patients with probable…
-
Lundbeck to acquire Longboard Pharmaceuticals for $2.6bn
Lundbeck has signed an agreement to acquire Longboard Pharmaceuticals for $2.6bn equity value in a move set to enhance its…
-
Genentech’s Evrysdi helped babies with SMA reach rare milestones in Phase II trial
Roche’s spinal muscular atrophy (SMA) drug Evrysdi (risdiplam) has helped pre-symptomatic babies reach rare milestones after two years of treatment…
